OPKO Health Management
Management criteria checks 3/4
OPKO Health's CEO is Phil Frost, appointed in Mar 2007, has a tenure of 17.75 years. total yearly compensation is $2.28M, comprised of 42.2% salary and 57.8% bonuses, including company stock and options. directly owns 36.6% of the company’s shares, worth $371.81M. The average tenure of the management team and the board of directors is 9.8 years and 15.7 years respectively.
Key information
Phil Frost
Chief executive officer
US$2.3m
Total compensation
CEO salary percentage | 42.2% |
CEO tenure | 17.8yrs |
CEO ownership | 36.6% |
Management average tenure | 9.8yrs |
Board average tenure | 15.7yrs |
Recent management updates
Recent updates
OPKO Health, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09Not Enough To Keep OPKO Health Flying
Aug 28OPKO Health, Inc. (NASDAQ:OPK) Not Flying Under The Radar
Dec 30Is OPKO Health (NASDAQ:OPK) A Risky Investment?
Oct 03OPKO Health, Inc.'s (NASDAQ:OPK) 28% Share Price Surge Not Quite Adding Up
Jul 24Would OPKO Health (NASDAQ:OPK) Be Better Off With Less Debt?
Jun 07Is OPKO Health (NASDAQ:OPK) Using Too Much Debt?
Jan 04OPKO Health: Assessing If Significant Potential Can Be Realized
Sep 15OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Sep 05OPKO Health: 14%+ Short Interest Means More Volatility Over The Near Term
Jun 21OPKO Health (NASDAQ:OPK) Is Carrying A Fair Bit Of Debt
Apr 29OPKO Health: A Great Long-Term Investment In Health
Apr 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$134m |
Jun 30 2024 | n/a | n/a | -US$243m |
Mar 31 2024 | n/a | n/a | -US$252m |
Dec 31 2023 | US$2m | US$960k | -US$189m |
Sep 30 2023 | n/a | n/a | -US$208m |
Jun 30 2023 | n/a | n/a | -US$209m |
Mar 31 2023 | n/a | n/a | -US$291m |
Dec 31 2022 | US$972k | US$960k | -US$328m |
Sep 30 2022 | n/a | n/a | -US$317m |
Jun 30 2022 | n/a | n/a | -US$202m |
Mar 31 2022 | n/a | n/a | -US$117m |
Dec 31 2021 | US$2m | US$960k | -US$30m |
Sep 30 2021 | n/a | n/a | US$76m |
Jun 30 2021 | n/a | n/a | US$71m |
Mar 31 2021 | n/a | n/a | US$121m |
Dec 31 2020 | US$2m | US$960k | US$31m |
Sep 30 2020 | n/a | n/a | -US$114m |
Jun 30 2020 | n/a | n/a | -US$200m |
Mar 31 2020 | n/a | n/a | -US$293m |
Dec 31 2019 | US$1m | US$960k | -US$315m |
Sep 30 2019 | n/a | n/a | -US$279m |
Jun 30 2019 | n/a | n/a | -US$244m |
Mar 31 2019 | n/a | n/a | -US$191m |
Dec 31 2018 | US$2m | US$960k | -US$153m |
Sep 30 2018 | n/a | n/a | -US$295m |
Jun 30 2018 | n/a | n/a | -US$303m |
Mar 31 2018 | n/a | n/a | -US$314m |
Dec 31 2017 | US$971k | US$960k | -US$305m |
Compensation vs Market: Phil's total compensation ($USD2.28M) is about average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.
CEO
Phil Frost (88 yo)
17.8yrs
Tenure
US$2,277,200
Compensation
Dr. Phillip Frost, also known as Phil, M.D., Ph D., is Director of Non-Invasive Monitoring Systems, Inc. since June 01, 2023. He has been the Chairman, Chief Executive Officer and Director of OPKO Health,...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 17.8yrs | US$2.28m | 36.6% $ 371.8m | |
Vice Chairman & Chief Technical Officer | 17.8yrs | US$2.19m | 4.92% $ 50.0m | |
President & Vice Chairman | 2.6yrs | US$2.19m | 3.03% $ 30.8m | |
Senior VP | 17.8yrs | US$1.81m | 0.027% $ 270.5k | |
Executive VP of Administration & Director | 17.6yrs | US$1.94m | 0.92% $ 9.3m | |
Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal | 7.8yrs | no data | no data | |
Chief Innovation Officer & Director | 2.6yrs | no data | 5.99% $ 60.9m | |
Chief Medical Officer | less than a year | no data | no data | |
Chief Executive Officer of OPKO Renal | 11.8yrs | no data | no data | |
President of Transition Therapeutics | no data | no data | no data | |
President of OPKO Health Iberoamerica | no data | no data | no data | |
Chief Executive Officer of EirGen Pharma | 5.1yrs | no data | no data |
9.8yrs
Average Tenure
71.5yo
Average Age
Experienced Management: OPK's management team is seasoned and experienced (9.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 17.8yrs | US$2.28m | 36.6% $ 371.8m | |
Vice Chairman & Chief Technical Officer | 17.8yrs | US$2.19m | 4.92% $ 50.0m | |
President & Vice Chairman | 2.6yrs | US$2.19m | 3.03% $ 30.8m | |
Executive VP of Administration & Director | 17.8yrs | US$1.94m | 0.92% $ 9.3m | |
Chief Innovation Officer & Director | 2.6yrs | no data | 5.99% $ 60.9m | |
Independent Director | 4yrs | US$69.90k | 0% $ 0 | |
Lead Independent Director | 16.9yrs | US$134.80k | 0.048% $ 490.8k | |
Independent Director | 7.8yrs | US$92.40k | 0.015% $ 156.0k | |
Independent Director | 21yrs | US$84.90k | 0.058% $ 594.2k | |
Independent Director | 3.8yrs | US$92.40k | 0% $ 0 | |
Independent Director | 15.7yrs | US$62.40k | 0.0099% $ 100.4k |
15.7yrs
Average Tenure
77yo
Average Age
Experienced Board: OPK's board of directors are seasoned and experienced ( 15.7 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 04:14 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OPKO Health, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Petusky | Barrington Research Associates, Inc. |
Louise Chen | Cantor Fitzgerald & Co. |
Dana Flanders | Guggenheim Securities, LLC |